Patent ID: 11952634
Assignee: MEDIVATION PROSTATE THERAPEUTICS LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating triple negative breast cancer (TNBC) in a subject, said subject having a breast cancer comprising breast cancer cells that have been classified as other than basal-like subtype, said method comprising:
testing the subject to determine a Weighted Basal and Luminal A classifier score of breast cancer cells of the subject; and
administering a breast cancer treatment to the subject comprising an androgen receptor inhibitor, thereby treating the triple negative breast cancer in the subject;
wherein the triple negative breast cancer cells of the subject are characterized by a Weighted Basal and Luminal A classifier score greater than −0.3 according to the formula:

Weighted Basal and Luminal A classifier score=−0.25(Basal Centroid classifier score)+0.27(Luminal A Centroid classifier score), wherein said Basal Centroid classifier score and said Luminal A Centroid classifier score are determined for the triple negative breast cancer cells of the subject from the expression by said cells of the set of intrinsic genes listed in Table 1 using a PAM50 classifier and detecting the set of intrinsic genes by RNA sequencing.